NASDAQ:EKSO Ekso Bionics (EKSO) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free EKSO Stock Alerts $1.28 +0.10 (+8.47%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.18▼$1.2850-Day Range$1.16▼$2.1052-Week Range$0.62▼$3.13Volume104,657 shsAverage Volume187,310 shsMarket Capitalization$22.91 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ekso Bionics alerts: Email Address Ekso Bionics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside658.2% Upside$9.25 Price TargetShort InterestHealthy1.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector779th out of 907 stocksGeneral Industrial Machinery, Industry6th out of 8 stocks 3.5 Analyst's Opinion Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEkso Bionics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.06% of the outstanding shares of Ekso Bionics have been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently increased by 41.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EKSO. Previous Next 0.8 News and Social Media Coverage News SentimentEkso Bionics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ekso Bionics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EKSO on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 6.42% of the stock of Ekso Bionics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ekso Bionics are expected to grow in the coming year, from ($0.49) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Ekso Bionics Stock (NASDAQ:EKSO)Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.Read More EKSO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EKSO Stock News HeadlinesApril 22, 2024 | globenewswire.comEkso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024April 16, 2024 | americanbankingnews.comEkso Bionics (NASDAQ:EKSO) Stock Crosses Below 50-Day Moving Average of $1.65April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 13, 2024 | investing.comEkso Bionics secures Medicare reimbursement for exoskeletonApril 12, 2024 | globenewswire.comEkso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego PersonalApril 4, 2024 | morningstar.comEkso Bionics Holdings IncMarch 19, 2024 | finanznachrichten.deMedical Robots Market Worth $33.8 billion | MarketsandMarketsMarch 16, 2024 | uk.investing.comEkso Bionics director Lathan Corinna buys shares worth $15.5kApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 11, 2024 | finance.yahoo.comGlobal Exoskeleton Research Report 2023: From Concept to Reality - Advancements and Challenges in Exoskeleton Developments with Forecasts to 2035March 6, 2024 | marketwatch.comEkso Bionics Shares Fall on Delayed CMS Payment DeterminationMarch 6, 2024 | finance.yahoo.comEkso Bionics Holdings Full Year 2023 Earnings: EPS Misses ExpectationsMarch 5, 2024 | finanznachrichten.deEkso Bionics Holdings, Inc.: Ekso Bionics Reports Record Annual Revenue of $18.3 MillionMarch 5, 2024 | seekingalpha.comEkso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comEkso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | investorplace.comEKSO Stock Earnings: Ekso Bionics Holdings Misses EPS, Beats Revenue for Q4 2023March 4, 2024 | benzinga.comRecap: Ekso Bionics Holdings Q4 EarningsMarch 4, 2024 | globenewswire.comEkso Bionics Reports Record Annual Revenue of $18.3 MillionMarch 3, 2024 | msn.comEkso Bionics Holdings Q4 Earnings PreviewMarch 3, 2024 | markets.businessinsider.comEkso Bionics earnings preview: what to expectFebruary 26, 2024 | finance.yahoo.comEkso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024February 24, 2024 | msn.comEkso Bionics Holdings (EKSO) Price Target Increased by 11.11% to 10.20February 21, 2024 | wsj.comEkso Bionics Holdings Inc.February 6, 2024 | msn.comHere's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock NowJanuary 25, 2024 | benzinga.com(EKSO) - Analyzing Ekso Bionics Holdings's Short InterestJanuary 23, 2024 | investing.comEkso Bionics Holdings Inc (EKSO)January 23, 2024 | finance.yahoo.comWhen Will Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Become Profitable?See More Headlines Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/25/2024Next Earnings (Confirmed)4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry General industrial machinery, Sub-IndustryN/A Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone(510) 984-1761Fax510-927-2647Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$9.25 High Stock Price Target$9.25 Low Stock Price Target$9.25 Potential Upside/Downside+683.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,200,000.00 Net Margins-83.14% Pretax Margin-83.14% Return on Equity-90.80% Return on Assets-46.34% Debt Debt-to-Equity Ratio0.38 Current Ratio2.49 Quick Ratio1.87 Sales & Book Value Annual Sales$18.28 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book1.39Miscellaneous Outstanding Shares17,900,000Free Float16,560,000Market Cap$21.12 million OptionableOptionable Beta1.61 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Scott G. Davis (Age 54)CEO & Director Comp: $535.8kMr. Jerome Wong (Age 50)Corporate Controller, Corporate Secretary & CFO Comp: $356.81kMr. Jason C. JonesChief Operating OfficerMs. Rachael AndersonGlobal Director of Marketing & Strategic GrowthMr. Anthony PrattVice President of SalesMs. Ann CooksonHuman Resources DirectorMs. Foon Lim ChweePresident of APACMr. Stephan AderholdSenior VP & GM of EMEAMore ExecutivesKey CompetitorsAIM ImmunoTechNYSE:AIMOnconova TherapeuticsNASDAQ:ONTXAccelerate DiagnosticsNASDAQ:AXDXVincerx PharmaNASDAQ:VINCGlucoTrackNASDAQ:GCTKView All CompetitorsInsiders & InstitutionsKent Lake Capital LLCBought 141,158 shares on 2/14/2024Ownership: 0.951%Essex Investment Management Co. LLCSold 62,858 shares on 2/8/2024Ownership: 1.062%Simplex Trading LLCBought 5,000 shares on 2/2/2024Ownership: 0.000%Scott G DavisSold 37,446 sharesTotal: $37,446.00 ($1.00/share)Jerome WongSold 12,784 sharesTotal: $12,784.00 ($1.00/share)View All Insider TransactionsView All Institutional Transactions EKSO Stock Analysis - Frequently Asked Questions Should I buy or sell Ekso Bionics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks. What is Ekso Bionics' stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Ekso Bionics' shares. Their EKSO share price targets range from $9.25 to $9.25. On average, they expect the company's share price to reach $9.25 in the next year. This suggests a possible upside of 658.2% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts. How have EKSO shares performed in 2024? Ekso Bionics' stock was trading at $2.50 at the beginning of 2024. Since then, EKSO shares have decreased by 51.2% and is now trading at $1.22. View the best growth stocks for 2024 here. Are investors shorting Ekso Bionics? Ekso Bionics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 190,300 shares, an increase of 41.7% from the March 31st total of 134,300 shares. Based on an average daily volume of 166,000 shares, the short-interest ratio is presently 1.1 days. View Ekso Bionics' Short Interest. When is Ekso Bionics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024. View our EKSO earnings forecast. How can I listen to Ekso Bionics' earnings call? Ekso Bionics will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its quarterly earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.11. The business had revenue of $4.85 million for the quarter, compared to the consensus estimate of $4.80 million. Ekso Bionics had a negative net margin of 83.14% and a negative trailing twelve-month return on equity of 90.80%. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. When did Ekso Bionics' stock split? Ekso Bionics shares reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA). How do I buy shares of Ekso Bionics? Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EKSO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ekso Bionics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
